Your browser doesn't support javascript.
Integration of advanced methods and models to study drug absorption and related processes: An UNGAP perspective.
Wilson, Clive G; Aarons, Leon; Augustijns, Patrick; Brouwers, Joachim; Darwich, Adam S; De Waal, Tom; Garbacz, Grzegorz; Hansmann, Simone; Hoc, Dagmara; Ivanova, Anela; Koziolek, Mirko; Reppas, Christos; Schick, Philipp; Vertzoni, Maria; García-Horsman, J Arturo.
  • Wilson CG; Strathclyde Institute of Pharmacy & Biomedical Sciences, Glasgow, UK. Electronic address: clivegwilson@mac.com.
  • Aarons L; University of Manchester, Manchester, UK. Electronic address: Leon.Aarons@manchester.ac.uk.
  • Augustijns P; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium. Electronic address: patrick.augustijns@kuleuven.be.
  • Brouwers J; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium.
  • Darwich AS; KTH Royal Institute of Technology, Stockholm, Sweden. Electronic address: darwich@kth.se.
  • De Waal T; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium. Electronic address: tom.dewaal@kuleuven.be.
  • Garbacz G; Physiolution Polska, Wroclaw, Poland. Electronic address: g.garbacz@physiolution.pl.
  • Hansmann S; Merck Healthcare KGaA, Darmstadt, Germany. Electronic address: simone.hansmann@merckgroup.com.
  • Hoc D; Physiolution Polska, Wroclaw, Poland. Electronic address: dhoc@physiolution.pl.
  • Ivanova A; Sofia University St. Kliment Ohridski, Bulgaria. Electronic address: aivanova@chem.uni-sofia.bg.
  • Koziolek M; NCE Formulation Sciences, Abbvie Deutschland GmbH & Co. KG, Germany. Electronic address: mirko.koziolek@abbvie.com.
  • Reppas C; National and Kapodistrian University of Athens, Athens, Greece. Electronic address: reppas@pharm.uoa.gr.
  • Schick P; Department of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, University of Greifswald, Germany. Electronic address: jedamzikp@uni-greifswald.de.
  • Vertzoni M; National and Kapodistrian University of Athens, Athens, Greece. Electronic address: vertzoni@pharm.uoa.gr.
  • García-Horsman JA; Division of Pharmacology and Pharmacotherapy, University of Helsinki, Finland. Electronic address: arturo.garcia@helsinki.fi.
Eur J Pharm Sci ; 172: 106100, 2022 May 01.
Article in English | MEDLINE | ID: covidwho-1587878
ABSTRACT
This collection of contributions from the European Network on Understanding Gastrointestinal Absorption-related Processes (UNGAP) community assembly aims to provide information on some of the current and newer methods employed to study the behaviour of medicines. It is the product of interactions in the immediate pre-Covid period when UNGAP members were able to meet and set up workshops and to discuss progress across the disciplines. UNGAP activities are divided into work packages that cover special treatment populations, absorption processes in different regions of the gut, the development of advanced formulations and the integration of food and pharmaceutical scientists in the food-drug interface. This involves both new and established technical approaches in which we have attempted to define best practice and highlight areas where further research is needed. Over the last months we have been able to reflect on some of the key innovative approaches which we were tasked with mapping, including theoretical, in silico, in vitro, in vivo and ex vivo, preclinical and clinical approaches. This is the product of some of us in a snapshot of where UNGAP has travelled and what aspects of innovative technologies are important. It is not a comprehensive review of all methods used in research to study drug dissolution and absorption, but provides an ample panorama of current and advanced methods generally and potentially useful in this area. This collection starts from a consideration of advances in a priori approaches an understanding of the molecular properties of the compound to predict biological characteristics relevant to absorption. The next four sections discuss a major activity in the UNGAP initiative, the pursuit of more representative conditions to study lumenal dissolution of drug formulations developed independently by academic teams. They are important because they illustrate examples of in vitro simulation systems that have begun to provide a useful understanding of formulation behaviour in the upper GI tract for industry. The Leuven team highlights the importance of the physiology of the digestive tract, as they describe the relevance of gastric and intestinal fluids on the behaviour of drugs along the tract. This provides the introduction to microdosing as an early tool to study drug disposition. Microdosing in oncology is starting to use gamma-emitting tracers, which provides a link through SPECT to the next section on nuclear medicine. The last two papers link the modelling approaches used by the pharmaceutical industry, in silico to Pop-PK linking to Darwich and Aarons, who provide discussion on pharmacometric modelling, completing the loop of molecule to man.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Gastrointestinal Tract / COVID-19 Type of study: Prognostic study Limits: Humans / Male Language: English Journal: Eur J Pharm Sci Journal subject: Pharmacy / Pharmacology / Chemistry Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Gastrointestinal Tract / COVID-19 Type of study: Prognostic study Limits: Humans / Male Language: English Journal: Eur J Pharm Sci Journal subject: Pharmacy / Pharmacology / Chemistry Year: 2022 Document Type: Article